| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.13 | 0.009 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.083 | 0.08 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.08 | 0.08 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.059 | 0.2 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.057 | 0.2 |